GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » Research & Development

Exact Therapeutics AS (OSL:EXTX) Research & Development : kr19.74 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Exact Therapeutics AS's Research & Development for the six months ended in Dec. 2023 was kr12.26 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was kr19.74 Mil.

Exact Therapeutics AS Research & Development Historical Data

The historical data trend for Exact Therapeutics AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS Research & Development Chart

Exact Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 14.54 13.31 34.50 19.91 19.74

Exact Therapeutics AS Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 17.43 15.88 4.03 7.47 12.26

Exact Therapeutics AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr19.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Therapeutics AS  (OSL:EXTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Exact Therapeutics AS Research & Development Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Therapeutics AS (OSL:EXTX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » Research & Development
Comparable Companies
OSL:CIRCA OSL:TRMED OSL:LYTIX OSL:BGBIO OSL:ABS OSL:PCIB OSL:ABTEC OSL:SOFTX OSL:CRNA OSL:HBC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Ostre Aker vei 19, Oslo, NOR, 0581
Website
https://www.exact-tx.com
Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines